Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,078	$ 5,847
General and administrative	5,640	2,312
Total operating expenses	18,718	8,159
Loss from operations	(17,844)	(7,683)
Other income/(expense):
Interest income	4,222	606
Loss on currency exchange, net	(12)	(9)
Other expense	(114)	(3)
Total other income	4,096	594
Net loss	$ (13,748)	$ (7,089)
Net loss per share attributable to common stockholders, basic	$ (0.54)	$ (8.1)
Net loss per share attributable to common stockholders, diluted	$ (0.54)	$ (8.1)
Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, basic	25,665,475	874,709
Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, diluted	25,665,475	874,709
Comprehensive loss:
Net Income (Loss)	$ (13,748)	$ (7,089)
Other comprehensive (loss)/income:
Change in unrealized (losses)/gains related to available-for-sale debt securities	(74)	104
Total other comprehensive (loss)/income	(74)	104
Total comprehensive loss	(13,822)	(6,985)
Related Party [Member]
Revenues:
License revenue - related party	$ 874	$ 476